// App-Quantinova.ai

1145 : Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Researchers

Presenter

  • Gilles Salles

Principal Investigators

  • Ka Lung Wu

  • Sofya Kovalchuk

  • Santiago Mercadal

  • Annalisa Chiarenza

  • Ruth Pettengell

  • Elisabeth Vandenberghe

  • Paolo Corradini

  • Susana Carvalho

  • Christophe De Belder

  • Rikisha Shah Gupta

  • Anna van Troostenburg

  • Nishanthan Rajakumaraswamy

  • Heribert Ramroth

Medical Centers

  • Hospices Civils de Lyon, Universite Claude Bernard, Pierre Benite, France

  • Ziekenhuis Netwerk Antwerpen Stuivenberg,Antwerp,Belgium

  • Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

  • ICO-Hospital Duran i Reynals, LHospitalet de Llobregat, Spain

  • A.O.U. Policlinico Vittorio Emanuele, University of Catania, Division of Hematology, Catania, Italy

  • Clinical Sciences, St. George's Hospital, London, United Kingdom

  • Haematology, St James Hospital, Dublin, Ireland

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Instituto Portugues de Oncologia de Lisboa, Lisbon, Portugal

  • Clinical Operations Late Phase, Gilead Sciences Europe, Ltd., London, United Kingdom

  • Data Science and Biometrics/Epidemiology, Gilead Sciences, Ltd., London, United Kingdom

  • Global Patient Safety, Gilead Sciences GmbH, Munich, Germany

  • Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA

Locations

  • France

  • Belgium

  • Italy

  • Spain

  • United Kingdom

  • Ireland

  • Portugal

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Multifocal leukoencephalopathy

  • Stevens Johnson syndrome

  • Follicular lymphoma

  • Pulmonary alveolar proteinosis

  • Lymphomas

  • Ulcerative colitis

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • Idelalisib

Outcome

  • N/A

Study Design

  • Non Interventional

  • Cohort

Phase

  • III

Study Id's

  • NCT01282424

  • NCT03568929

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved